Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Unilever shares fall on 'subdued' outlook, earnings miss

(Sharecast News) - Multinational consumer goods company Unilever on Thursday said it expected a slow start to the current financial year with "subdued" market growth in the near term and announced a €1.5bn share buyback, while fourth-quarter underlying sales just missed estimates.

Underlying sales grew 4%, compared with forecasts of 4.1% in a company-compiled poll. Unilever now expects full year 2025 growth within its multi-year range of 3% - 5%. Unilever shares fell 7% in London trade.

Full-year underlying sales grew 4.2% versus a consensus of 4.3%, driven by volume growth of 2.8%. Underlying operating margins came in at 18.4% against the estimated 18.3%.

"We expect the market and our growth to improve during the year as price increases, reflecting higher commodity costs in 2025. We expect a more balanced split between volume and price," the maker of Dove soap said.

"Market growth, which slowed throughout 2024, is expected to remain soft in the first half of 2025," he added.

It added that the ice-cream business, which includes the Ben & Jerry's and Magnum brands, would be separated via a demerger and listed in Amsterdam, London and New York.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.